Protalix BioTherapeutics, Inc.

Chiesi Farmaceutici S.p.A. is actively expanding its rare disease business in Japan through a subsidiary established there in 2022 and as part of the family-owned Italian firm's global push into this

Biogen/Ionis’s Tofersen For SOD1 ALS Away from its adventures in Alzheimer’s disease, Biogen Pharma is hopeful of an accelerated US approval for tofersen, which it licensed from Ionis Pharmaceutica

With its acquisition of Ireland's Amryt Pharma set to complete shortly after Easter, Chiesi Farmaceutici S.p.A. can expect a healthy rise in revenues for 2023 having just posted a strong set of fi

Chiesi Farmaceutici S.p.A. is revisiting its respiratory heritage, teaming up with Sweden's Affibody AB to develop inhaled drugs in a deal that could be worth over $640m. Under the terms of the agr